Target intelligence / Profile preview

Cofilin-1 (CFL1)

Target
CFL1
Molecular classification
Actin-binding protein, Microfilament protein, Cytoskeletal regulator, Other (Actin depolymerizing factor/ADF-cofilin family)
01

Overview

Cofilin-1 is a small, highly conserved, non-muscle actin-binding protein that is a central regulator of actin filament dynamics. It severs and depolymerizes filamentous (F-) actin and also inhibits the polymerization of monomeric (G-) actin, an activity modulated by its phosphorylation at serine-3 by LIM kinases. Cofilin-1 is involved in controlling cell shape, motility, division, nuclear actin transport, and transcriptional regulation. Its activity is essential for processes such as cytokinesis, migration, and neuronal development. Dysregulated cofilin-1 function has been implicated in cancer metastasis, neurodegenerative disorders, and other diseases involving aberrant cytoskeletal remodeling. As a result, it is considered a potential, though challenging, therapeutic target because systemic inhibition may disrupt fundamental cell functions[1][2][3][4][5][8].

Other names
Cofilin 1CFL1CFLp1818 kDa phosphoproteinCofilinNon-muscle isoform cofilinHEL-S-15Epididymis secretory protein Li 15
02

Mechanism of action

Drugs or tool compounds affecting CFL1 act by modulating actin filament turnover through direct inhibition or activation (via phosphorylation/serine-3) or via upstream kinase inhibition (e.g., LIM kinase) Compounds influencing the actin cytoskeleton, migration, or invasion may indirectly affect CFL1 function

03

Biological functions

Actin cytoskeleton organizationRegulation of actin polymerization and depolymerizationCell motilityCell division and cytokinesisApoptosisGene expression/transcription regulationNuclear transport of actin
04

Disease associations

CancerNeurodegenerative diseaseCongenital/malformation syndromes (Smith-Lemli-Opitz syndrome, Baraitser-Winter syndrome)Other (potential roles in kidney and cardiovascular disease, per family involvement[4])
05

Safety considerations

Targeting CFL1 or actin dynamics broadly may cause toxicity due to interference with essential processes such as cell division, migration, and viability, given its ubiquitous cellular role
06

Interacting drugs

No direct FDA-approved drugs, but modulation by small molecule inhibitors of upstream kinases (e.g., LIM kinase inhibitors) and research compounds targeting actin dynamics
07

Biomarkers

Phosphorylation state of CFL1 (i.e., pSer3-CFL1) as a readout of pathway activationCytoskeletal remodeling markers in cancer or neurodegeneration

Beyond the preview

Go deeper on Cofilin-1 (CFL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cofilin-1 (CFL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call